Santaris Reports Lower Q2 Losses on Lower Expenses, Data on Inflammatory Disease-Associated miRNA
July 16, 2009
Santaris Reports Lower Q2 Losses on Lower Expenses, Data on Inflammatory Disease-Associated miRNA
In the advance online version of Nucleic Acids Research, Santaris investigators reported data identifying miR-155, an miRNA involved in immune-system regulation, as a possible therapeutic target for chronic inflammatory diseases such as rheumatoid arthritis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News - People in the News: Soren Tulstrup, Henrik Stage
May 31, 2012 / Gene Silencing News - With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News - Santaris to Present Phase IIa Data on HCV Drug
April 19, 2012 / Gene Silencing News - UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News